Shares of Æterna Zentaris (AEZS) Soar on Positive Outlook

Æterna Zentaris, Inc. (Nasdaq:AEZS) shares are rocking today, following a bullish article on Seeking Alpha. The stock popped about 4.7% to $1.79, but has since receded a little.

The article highlights five key points that could still pack a potential 200% to 300% of upside into the stock. First, the author highlights that AEZS is in a healthy cash position, enough to fund upcoming trials and filings. They continue that AEZS is planning a New Drug Application with the U.S. FDA for Solorel, which is currently in Phase 3 testing and under a Special Protocol Assessment (SPA) with the FDA.

Further, perifisone is also in Phase 3, and has SPA, orphan-drug designation, and Fast-Track review from the FDA. An NDA filing is expected in 2012.




Full Story